Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in HRAS-mutant advanced non-hematological malignancies
NCT02383927Phase 2Completed
- Sponsor
- Kura Oncology
- Start
- May 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of tipifarnib in thyroid cancer, head and neck squamous cell carcinoma (HNSCC) and squamous cell carcinoma (SCC) (3 cohorts), sponsored by Kura Oncology. Primary endpoint: Objective Response Rate up to 3 years. Started May 2015; status: completed.
02
Drugs
tipifarnib
03
Conditions
thyroid cancerhead and neck squamous cell carcinoma (HNSCC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT02383927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383927.